Fabrazyme is used to treat patients with Fabry disease, a disorder that results from a deficiency in the enzyme alpha-galactosidase A or alpha- GAL. Fabrazyme is infused with the purpose of replacing the missing enzyme in the patient. Fabrazyme works by lowering the amount of globotriaosylceramide (GL-3) which builds up in cells, lining the blood vessels of the kidney. Fabrazyme is infused every two weeks intravenously with the dosage depending on the patient’s body weight.

 

See all infusion medications